The global DNA Methylation market size was estimated to be US$ 1.25 billion in 2021 and is expected grow at a CAGR of 15% between 2023 to 2032.
The process of adding methyl groups to the DNA molecule is known as DNA methylation. This alters how genes are expressed and causes some genes to be silenced. It is crucial for many biological processes, including X-chromosome inactivation, genomic imprinting, cell differentiation, and embryogenesis. DNA methylation has also been linked to several illnesses, including cancer, neurological disorders, and cardiovascular conditions.
Using the DNA methylation analysis method, researchers can identify possible biomarkers and learn a lot about regulating genes. Obesity, cancer, and other disease processes have all been linked to abnormal DNA methylation. Additionally, it offers the possibility for use in agronomic research to examine how crops react to drought, temperature extremes, and other environmental disturbances.
Covid 19 impact:
Lockdowns and other limitations brought on by the COVID-19 epidemic slowed down research and testing at labs and research facilities worldwide. DNA methylation has, nevertheless, expanded due to the reopening of academic and research institutes. Additionally, the availability of various DNA methylation test kits via e-Commerce channels has created new potential for industry participants. Further, this has caused academic institutions to use DNA methylation more frequently.
Market Growth Drivers:
Demand is driven by the growing use of DNA methylation in numerous sequencing techniques such as pyrosequencing, Illumina sequencing, Ion-Torrent, and Oxford Nanopore sequencing. Furthermore, DNA methylation is a common epigenetic biomarker in oncology research labs worldwide.
Due to the rising incidence of various diseases worldwide, DNA methylation technology is being utilized more and more in academic settings and cancer research. Alternative diagnostic techniques are also being used to identify genetic abnormalities early on. These are a few critical variables anticipated to influence market revenue growth in the future significantly.
The global DNA methylation market is divided into categories based on technique, including bisulfite DNA modification, methylated DNA immunoprecipitation, High-resolution Melt (HRM) analysis, and others. During the forecast period, the bisulfite DNA modification category is anticipated to hold the most significant revenue share in the worldwide DNA methylation market. As it chemically transforms unmethylated cytosine into uracil, whereas methylated cytosine is shielded from this alteration, the bisulfite DNA modification approach for DNA methylation research is increasingly used for single-nucleotide resolution and genome-wide investigations.
Over the projection period, the Methylated DNA Immunoprecipitation (I.P.) segment is anticipated to post consistent revenue growth. An increase in the use of immunoprecipitated methylated DNA in qPCR, sequencing, amplification, and hybridization investigations is driving growing demand. Utilizing antibodies against methylcytosine and antibody-binding beads, methylated DNA immunoprecipitation involves the immunoselection and precipitation of genomic DNA from cultured cells or tissues.
A new epigenome-wide DNA methylation analysis of COVID-19 patients used I.P. chips to uncover genes crucial to the development of the coronavirus disease. Since this method is reliable and repeatable, has a high enrichment yield, and is NGS-compatible, elastomers are also used in various research applications.
The global DNA methylation market is divided into segments based on applications, including DNA sequencing, oncology research, microarray, immunological assay, and others. During the forecast period, the DNA sequencing segment is anticipated to dominate the worldwide DNA methylation market in revenue. DNA methylation is increasingly used in DNA sequencing analyses, including pyrosequencing, Illumina sequencing, Ion-Torrent sequencing, and Oxford Nanopore sequencing.
Over the projection period, the oncology research segment is anticipated to experience consistent revenue growth. The need for DNA methylation as epigenetic biomarkers for early illness detection and diagnosis is rising due to the rising prevalence of various malignancies in patients around the world, which is projected to support the segment's revenue growth. Because epigenetic biomarkers are widely used in the drug discovery industry and during clinical treatment, their demand is anticipated to remain high. Epigenetic biomarkers measure epigenetic alterations associated with any disease or medication.
The biotechnology sector, pharmaceutical industry, academic institutions, research laboratories, and others are the end-use segments of the worldwide DNA methylation market. In terms of revenue during the forecast period, the biotechnology industry segment is anticipated to take the lead.
The biotechnology sector uses the DNA methylation approach more frequently due to rising demand for it in genomic research, gene-specific and genome-wide analyses, agronomic studies, and next-generation sequencing technologies. Due to its ability to be employed as an epigenetic biomarker, DNA methylation is also used as a clinical diagnostic tool for detecting chromosomal abnormalities or genetic illnesses. These elements are anticipated to fuel the segment's revenue growth.
Over the forecast period, the segment for research laboratories is anticipated to experience consistent revenue growth. The demand for DNA methylation as a critical oncogenic research tool is rising due to an increase in oncology research due to the rising prevalence of various cancers in patients around the world, which is anticipated to accelerate the segment's revenue growth.
The global DNA methylation market is divided into several product categories, including enzymes, reagents, kits, instruments, consumables, and others. In terms of revenue over the forecast period, the enzymes segment is anticipated to take the lead. Enzyme utilization in biotechnology has increased due to the rising demand for DNA and protein-modifying enzymes in the DNA methylation technique used in genomic research, gene-specific and genome-wide analyses, agronomic studies, and next-generation sequencing technologies. Due to their ability to speed up interactions between substrates to produce products, enzymes are crucial for catalyzing DNA methylation processes. These elements are anticipated to fuel the segment's revenue growth.
Over the projection period, the segment for reagents is anticipated to experience consistent revenue growth. Due to the requirement to conduct DNA methylation reactions in an aqueous medium containing a variety of substrates, the demand for reagents in DNA methylation techniques is rising, which is anticipated to support the segment's revenue growth.
During the forecast period, North America is anticipated to contribute a disproportionately more significant revenue share to the worldwide DNA methylation market. Due to its widespread use in several industries, DNA methylation is predicted to continue to be in high demand. DNA methylation as an epigenetic biomarker is rapidly expanding, which has increased its use in the research community. This is expected to increase the need for the technique.
Additionally, the region's intense concentration of important actors has enhanced the use of DNA methylation techniques in biotechnology. These elements are anticipated to fuel market revenue expansion in the area.
Over the forecast period, the Europe market is anticipated to have constant revenue growth. The technique's expanding use in oncology and epigenetic research labs propels the Europe DNA methylation market's expansion.
Due to the usage of DNA methylation as a promising diagnostic test in clinical research, Asia Pacific is anticipated to experience a consistent CAGR during the projection period. Single-cell transposable element methylation sequencing (scTEM-seq), created by researchers in this field, allows for the reasonably priced assessment of DNA methylation levels. This is anticipated to promote DNA methylation acceptance and accelerate the industry's growth. The pharmaceutical industry's explosive growth is also expected to fuel market revenue growth.
Growth Restraining Factors:
Biotechnology knowledge is insufficient to allow for the execution of DNA methylation experiments. Although DNA methylation in biotechnology has shown promising outcomes, there aren't many qualified lab personnel around. The low uptake of DNA methylation may constrain the growth of the DNA methylation market as a commercial diagnostic test.
Although it has shown promising findings in basic and applied genomics research, commercializing the method as a medical diagnostic tool has proven impossible.
Thermo-Fisher Scientific Inc, Agilent Technologies Inc, BioRad Laboratories Inc, Exact Sciences Corporation, QIAGEN N.V, Active Motif Inc, Illumina Inc, EpiGentek Group Inc, Pacific Biosciences Inc, New England Biolabs Inc, Merck KGaA, Zymo Research Corp, PerkinElmer Inc. and others.
Increasing cancer cases worldwide, decreasing treatment costs due to more product approvals, and considerable government assistance in financing global research and development activities are some of the key drivers driving the market expansion.
Stringent government policies for product approvals and high instrument costs are the restraints of the market.
A growing trend in methylation for precision medicine and technological advancements in methylation sequencing are some of the opportunities in the market.
The DNA methylation market is expected to grow with a 15% CAGR between 2023 to 2032.
The DNA methylation market size was estimated to be US$ 1.25 billion in 2021.
During the forecast period, North America is anticipated to contribute a disproportionately more significant revenue share to the worldwide DNA methylation market.
Copyright © 2023 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved